Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

PURPOSE: Lenalidomide and azacitidine are active in patients with lower- and higher-risk myelodysplastic syndromes (MDS). These agents may complement each other by targeting both the bone marrow microenvironment and hypomethylating action on the malignant clone. PATIENTS AND METHODS: This phase I tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sekeres, Mikkael A., List, Alan F., Cuthbertson, David, Paquette, Ronald, Ganetsky, Rebecca, Latham, Deborah, Paulic, Katarina, Afable, Manuel, Saba, Hussain I., Loughran, Thomas P., Maciejewski, Jaroslaw P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860439/
https://ncbi.nlm.nih.gov/pubmed/20354132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.0745
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars